Biologic Treatment Algorithms

Evidence-based pathways by disease state — drug class reference · ACR / EULAR / ECCO / AAD guidelines · Updated 2025

Drug class key
TNF inhibitor
IL-17A inhibitor
IL-12/23 or IL-23 p19 inhibitor
IL-6R inhibitor
IL-1 inhibitor
JAK inhibitor
T-cell co-stim inhibitor
Anti-integrin (α4β7)
Anti-CD20

Rheumatoid Arthritis

Moderate-to-severe disease with inadequate response to or intolerance of conventional DMARDs (e.g. methotrexate). Treat-to-target: remission or low disease activity.

1
First-line biologic
TNF inhibitor — preferred first biologic; combine with methotrexate when possible to reduce immunogenicity and improve outcomes. Monotherapy if methotrexate contraindicated.
TNF inhibitor
2
After TNF failure — switch mechanism
IL-6 receptor inhibitor, T-cell co-stimulation inhibitor, or anti-CD20 agent. If intolerance (not primary failure), a second TNF inhibitor is acceptable.
IL-6R inhibitorT-cell co-stim inhibitorAnti-CD20
3
Further refractory
JAK inhibitor — discuss cardiovascular and malignancy risk (age, smoking, prior cancer, thromboembolism history). Alternatively cycle remaining mechanisms not yet tried.
JAK inhibitor
✓
At any stage
Reassess response at 12–24 weeks. Continue conventional DMARD co-therapy where indicated. Biosimilars preferred per formulary.
Note: Prioritise biosimilars per local formulary. Therapeutic drug monitoring may guide anti-TNF dose optimisation. Screen for TB, hepatitis B, and ensure immunisations are up to date before initiating any biologic.

Juvenile Idiopathic Arthritis

Covers polyarticular (RF+ and RF−), extended oligoarticular, enthesitis-related (ERA), and systemic JIA subtypes. Subtype determines biologic class selection.

1
First-line — polyarticular / extended oligoarticular
TNF inhibitor — the first approved biologic class in JIA; typically combined with methotrexate. Well-established pediatric safety data.
TNF inhibitor
2
TNF failure — polyarticular
Switch to T-cell co-stimulation inhibitor or IL-6R inhibitor — both carry pediatric indications for polyarticular JIA.
T-cell co-stim inhibitorIL-6R inhibitor
3
Systemic JIA (sJIA) — with or without MAS
IL-1 inhibitor or IL-6R inhibitor preferred over TNF inhibitors. These are first-line for sJIA given the cytokine storm/MAS pathogenesis. Do not use TNF inhibitors as primary treatment in active sJIA.
IL-1 inhibitorIL-6R inhibitor
4
Enthesitis-related (ERA / juvenile AS)
TNF inhibitor first-line. IL-17A inhibitor for axial-predominant disease or after TNF failure — mirrors adult axSpA algorithm.
TNF inhibitorIL-17A inhibitor
Note: Age restrictions vary by individual agent — always verify pediatric approval and weight-based dosing. JAK inhibitor data in JIA are emerging; use within specialist guidance only. MAS = macrophage activation syndrome.

Ankylosing Spondylitis (radiographic axSpA)

Active disease (BASDAI ≥4 or ASDAS ≥2.1) despite trial of ≥2 NSAIDs at adequate dose for ≥4 weeks each. Conventional DMARDs have limited axial efficacy and are not required before biologic initiation.

1
First-line biologic
TNF inhibitor or IL-17A inhibitor — both are guideline-endorsed first choices with equivalent evidence for axial disease. Comorbidities guide selection: IBD or recurrent uveitis → favour TNF inhibitor (monoclonal); significant skin psoriasis → favour IL-17A inhibitor.
TNF inhibitorIL-17A inhibitor
2
After first biologic failure
Switch mechanism (TNF → IL-17A or IL-17A → TNF). A second TNF inhibitor is reasonable for intolerance (not primary failure).
TNF inhibitorIL-17A inhibitor
3
Refractory to ≥1 biologic
JAK inhibitor — approved in AS; assess cardiovascular and malignancy risk profile before initiating.
JAK inhibitor
Note: Reassess response at 12 weeks using BASDAI 50 or ASDAS improvement criteria. Combination with methotrexate does not improve axial outcomes and is not recommended.

Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Objective evidence of inflammation (elevated CRP and/or MRI sacroiliitis) plus active symptoms despite adequate NSAID trial. Structural damage not visible on plain X-ray.

1
First-line biologic
TNF inhibitor or IL-17A inhibitor — same principles as radiographic AS. Select agents with an approved nr-axSpA indication (not all agents in each class carry this label).
TNF inhibitorIL-17A inhibitor
2
After failure
Switch mechanism (TNF ↔ IL-17A). JAK inhibitor if further refractory — check approved indication.
TNF inhibitorIL-17A inhibitorJAK inhibitor
i
Key consideration
Objective evidence of inflammation is required before biologic initiation. Clinical response rates are similar to AS; whether biologics slow structural progression in nr-axSpA is less well established.
Note: Not all TNF inhibitor or IL-17A inhibitor agents hold an approved nr-axSpA indication — verify prescribing information before initiating.

Psoriatic Arthritis

Active PsA despite adequate conventional DMARD trial (methotrexate, leflunomide, or sulfasalazine ×3–6 months). Domain predominance (peripheral joint, axial, skin/nail, enthesitis, dactylitis) should inform class selection.

1
First-line biologic
TNF inhibitor, IL-17A inhibitor, or IL-12/23 inhibitor. Comorbidity and domain guide choice: IBD → TNF inhibitor; significant skin/nail or enthesitis → IL-17A inhibitor; skin/nail predominance with infrequent dosing preference → IL-12/23 inhibitor.
TNF inhibitorIL-17A inhibitorIL-12/23 inhibitor
2
After first biologic failure
Switch to alternative mechanism. Selective IL-23 p19 inhibitor is a strong option after TNF or IL-17A failure, with high skin and joint response rates.
TNF inhibitorIL-17A inhibitorIL-23 p19 inhibitor
3
Refractory disease
JAK inhibitor (assess CV/malignancy risk) or T-cell co-stimulation inhibitor (approved in PsA). PDE4 inhibitor is a non-biologic small molecule option at this stage.
JAK inhibitorT-cell co-stim inhibitor
Note: Reassess response at 12–24 weeks. For axial-predominant PsA, use AS algorithm. IL-17A inhibitors may worsen IBD — screen for GI symptoms at baseline.

Crohn's Disease

Moderate-to-severe disease (Harvey-Bradshaw ≥8, CDAI ≥220, or steroid-dependent/refractory). High-risk features (penetrating/stricturing, perianal, extensive small bowel, prior resection) warrant early aggressive/top-down therapy.

1
First-line biologic
TNF inhibitor (anti-TNF monoclonal antibody) — most widely used first-line agent with the broadest evidence base. Combine with an immunomodulator (azathioprine, 6-MP, or methotrexate) to reduce anti-drug antibody formation and improve durability.
TNF inhibitor (anti-TNF mAb)
2
After TNF failure or primary non-response
Anti-integrin (gut-selective α4β7 inhibitor) — preferred when infection risk is elevated or systemic immunosuppression is a concern. IL-12/23 inhibitor — preferred for fistulising disease, extraintestinal manifestations (joints, skin), or prior anti-TNF failure.
Anti-integrin (α4β7)IL-12/23 inhibitor
3
Further refractory
Selective IL-23 p19 inhibitor — approved in moderate-to-severe Crohn's. Cycle remaining mechanisms not yet tried. JAK inhibitor data in CD are limited; use within trial or specialist guidance.
IL-23 p19 inhibitor
✓
High-risk features — top-down approach
Early biologic initiation (before significant structural damage) recommended when any of the following are present: penetrating or stricturing behaviour, perianal disease, extensive small-bowel involvement, or prior intestinal resection.
Note: Therapeutic drug monitoring (TDM) is recommended for anti-TNF agents — proactive TDM improves outcomes and reduces antibody-related failure. Assess for mucosal healing as a treatment endpoint, not symptom response alone.

Ulcerative Colitis

Moderate-to-severe disease (Mayo score ≥6, endoscopic subscore ≥2) or steroid-dependent/refractory. Acute severe UC (ASUC) requires inpatient management.

1
First-line biologic
TNF inhibitor or anti-integrin (gut-selective α4β7 inhibitor). Anti-integrin is preferred when systemic immunosuppression is a concern (elderly patients, infection risk, hepatitis B carrier); it is not effective in Crohn's disease. Both have strong evidence bases in UC.
TNF inhibitorAnti-integrin (α4β7)
2
After failure of first biologic
Switch mechanism. JAK inhibitor has strong evidence and rapid onset in moderate-to-severe UC — suitable for patients needing quick response. Selective IL-23 p19 inhibitor for those where JAK inhibitor is not preferred (CV/malignancy risk).
JAK inhibitorIL-23 p19 inhibitor
3
Highly refractory / acute severe UC (inpatient)
Cycle remaining mechanisms. For ASUC inpatient: IV TNF inhibitor (anti-TNF monoclonal) or IV ciclosporin as rescue therapy in steroid-refractory disease. Reassess colectomy candidacy if no response within 3–5 days.
TNF inhibitor (IV rescue)
Note: TDM recommended for anti-TNF agents. Mucosal healing is the preferred endpoint. Reassess at 8–12 weeks. IL-23 inhibitor (risankizumab-class) approved in UC — use agents with confirmed UC indication.

Hidradenitis Suppurativa

Hurley Stage II–III, or Stage I refractory to topical/antibiotic therapy. Optimise surgical/procedural management (deroofing, wide excision) alongside systemic treatment. Address smoking and weight management.

1
First-line biologic
TNF inhibitor — first and best-established biologic class for HS. Reduces abscess and inflammatory nodule counts. Strong RCT evidence for anti-TNF monoclonal antibody in this setting.
TNF inhibitor
2
After TNF failure or contraindication
IL-17A inhibitor — approved in HS with demonstrated efficacy after anti-TNF failure. A meaningful alternative when TNF inhibitor is inadequate or not tolerated.
IL-17A inhibitor
3
Emerging / further refractory
IL-1 inhibitor and JAK inhibitors have emerging data in HS. A complement inhibitor (anti-C5aR class) has received regulatory approval in Europe for Hurley Stage II–III. Discuss with specialist in refractory cases.
IL-1 inhibitorJAK inhibitor
Note: Biological therapy complements, and does not replace, procedural management. Smoking cessation and weight reduction are the most impactful lifestyle interventions. Response assessment at 12–16 weeks using IHS4 or HiSCR.

Plaque Psoriasis

Moderate-to-severe disease (BSA >10%, DLQI >10, or special area involvement: scalp, nail, palmoplantar, genital). Inadequate response to or intolerance of phototherapy and/or conventional systemic agents (methotrexate, cyclosporine, acitretin).

1
First-line biologic
IL-17A inhibitor or IL-23 p19 inhibitor — highest skin clearance rates (PASI 90/100 responses); preferred for skin-predominant disease. TNF inhibitor is an acceptable first-line if PsA or IBD coexist, or where established long-term safety data are valued.
IL-17A inhibitorIL-23 p19 inhibitor
2
Alternative first-line
IL-12/23 inhibitor (less-frequent maintenance dosing) or TNF inhibitor (for patients with relevant comorbidities, pregnancy planning, or where more established long-term data preferred).
IL-12/23 inhibitorTNF inhibitor
3
After first biologic failure
Switch mechanism. IL-17A and IL-23 inhibitors can each rescue response after the other's failure. TNF inhibitor if not yet tried. Cycle remaining mechanisms not yet used.
IL-17A inhibitorIL-23 p19 inhibitorTNF inhibitor
✓
Special areas
Scalp, nail, palmoplantar, or genital involvement may justify biologic initiation at lower BSA thresholds given disproportionate quality-of-life impact. Reassess at 12–16 weeks.
Note: Psoriasis biologics generally do not require combination with a conventional DMARD. IL-17A inhibitors may worsen IBD — screen at baseline. Biosimilar TNF inhibitors are well established in psoriasis.
Comorbidity-guided class selection — quick reference
Concomitant IBD
Prefer TNF inhibitor · Avoid IL-17A inhibitors (may trigger/worsen IBD)
Recurrent anterior uveitis
Prefer TNF inhibitor (monoclonal) · TNF receptor fusion proteins less effective for uveitis
High infection risk / elderly
Consider Anti-integrin (α4β7) in IBD (gut-selective; lower systemic immunosuppression)
CV risk / prior malignancy
Exercise caution with JAK inhibitors · Use biologic preferentially; discuss risk-benefit
Demyelinating disease
Avoid TNF inhibitors · Use alternative mechanism (IL-6R, T-cell co-stim, IL-17A)
Pregnancy / planning
Established safety data generally favour TNF inhibitors · Certolizumab-class (no Fc) preferred · Discuss all agents with specialist
Disclaimer: These algorithms reflect major guideline frameworks (ACR, EULAR, ECCO, AAD, BSR) as of 2025 and are intended as a clinical decision-support reference only. They do not constitute prescribing advice. Individual treatment decisions must incorporate disease severity, comorbidities, patient preference, prior therapy history, local formulary, and shared decision-making. Drug class is referenced throughout — verify approved indications for specific agents before prescribing. This resource is not a substitute for specialist review.